REUTERS - AstraZeneca Pharma India Ltd
AstraZeneca said the delisting of the Indian unit and an increase in its ownership would provide it with "greater operational flexibility" to support the company's business in the local market.
AstraZeneca Pharma India's stock has risen nearly 50 percent from the year's low on January 30 to touch 1,092.35 rupees on Friday on delisting expectations, while the Mumbai market rose roughly 12 percent in that period.
The Indian unit's board approved the delisting proposal on March 18.
(Reporting by Zeba Siddiqui in MUMBAI; Editing by Sumeet Chatterjee)